...
机译:在植入多种可生物降解的聚合物药物后,对患者进行6个月对12个月的双抗血小板治疗的安全性和疗效治疗冠状动脉支架从I-Love-IT 2试验中进行亚群分析
Peoples Liberat Army Inst Cardiovasc Res Dept Cardiol Beijing Peoples R China;
Peoples Liberat Army Inst Cardiovasc Res Dept Cardiol Beijing Peoples R China;
Peoples Liberat Army Inst Cardiovasc Res Dept Cardiol Beijing Peoples R China;
Peoples Liberat Army Inst Cardiovasc Res Dept Cardiol Beijing Peoples R China;
Peoples Liberat Army Inst Cardiovasc Res Dept Cardiol Beijing Peoples R China;
Peoples Liberat Army Inst Cardiovasc Res Dept Cardiol Beijing Peoples R China;
Peoples Liberat Army Inst Cardiovasc Res Dept Cardiol Beijing Peoples R China;
机译:在植入多种可生物降解的聚合物药物后,对患者进行6个月对12个月的双抗血小板治疗的安全性和疗效治疗冠状动脉支架从I-Love-IT 2试验中进行亚群分析
机译:患有糖尿病患者的生物降解的聚合物Sirovulumus洗脱支架术后六个与双抗血小板治疗疗法的六个与二元抗血小板治疗
机译:患有糖尿病患者的生物降解的聚合物Sirovulumus洗脱支架术后六个与双抗血小板治疗疗法的六个与二元抗血小板治疗术:I-Love-IT 2审判的亚组分析
机译:生物可吸收聚合物雷帕霉素洗脱支架(Excel支架)对冠心病患者的临床疗效和安全性
机译:植入新一代生物可降解聚合物西罗莫司TARGET洗脱冠状动脉支架后的3个月和12个月双重抗血小板治疗的前瞻性多中心开放标签随机对照试验:TARGET DAPT试验方案
机译:将第二代药物洗脱支架植入Biolimus洗脱支架与Zotarolimus洗脱支架之后的TCT-8 6个月和12个月双重抗血小板治疗:前瞻性,随机,多中心试验